Cargando…

HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma

A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Oday T., Hassan, Wafaa S., Khayyat, Ahdab N., Almalki, Ahmad J., Sebaiy, Mahmoud M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794769/
https://www.ncbi.nlm.nih.gov/pubmed/33396585
http://dx.doi.org/10.3390/molecules26010129
_version_ 1783634286941831168
author Ali, Oday T.
Hassan, Wafaa S.
Khayyat, Ahdab N.
Almalki, Ahmad J.
Sebaiy, Mahmoud M.
author_facet Ali, Oday T.
Hassan, Wafaa S.
Khayyat, Ahdab N.
Almalki, Ahmad J.
Sebaiy, Mahmoud M.
author_sort Ali, Oday T.
collection PubMed
description A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was derived from the superiority of using the environmentally benign solvent, methanol over acetonitrile as a mobile phase component in respect of safety issues and migration times. Separation of the four anti-infective drugs was performed on a Thermo Scientific(®) BDS Hypersil C(8) column (5 µm, 2.50 × 4.60 mm) using a mobile phase consist of MeOH: 0.025 M KH(2)PO(4) (70:30, v/v) adjusted to pH 3.20 with ortho-phosphoric acid at room temperature. The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm. Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity. The method of analysis was validated according to Food and Drug Administration (FDA)guidelines for the determination of the drugs, either in their dosage forms with highly precise recoveries, or clinically in human plasma, especially regarding pharmacokinetic and bioequivalence studies.
format Online
Article
Text
id pubmed-7794769
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77947692021-01-10 HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma Ali, Oday T. Hassan, Wafaa S. Khayyat, Ahdab N. Almalki, Ahmad J. Sebaiy, Mahmoud M. Molecules Article A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was derived from the superiority of using the environmentally benign solvent, methanol over acetonitrile as a mobile phase component in respect of safety issues and migration times. Separation of the four anti-infective drugs was performed on a Thermo Scientific(®) BDS Hypersil C(8) column (5 µm, 2.50 × 4.60 mm) using a mobile phase consist of MeOH: 0.025 M KH(2)PO(4) (70:30, v/v) adjusted to pH 3.20 with ortho-phosphoric acid at room temperature. The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm. Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity. The method of analysis was validated according to Food and Drug Administration (FDA)guidelines for the determination of the drugs, either in their dosage forms with highly precise recoveries, or clinically in human plasma, especially regarding pharmacokinetic and bioequivalence studies. MDPI 2020-12-30 /pmc/articles/PMC7794769/ /pubmed/33396585 http://dx.doi.org/10.3390/molecules26010129 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ali, Oday T.
Hassan, Wafaa S.
Khayyat, Ahdab N.
Almalki, Ahmad J.
Sebaiy, Mahmoud M.
HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
title HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
title_full HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
title_fullStr HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
title_full_unstemmed HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
title_short HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
title_sort hplc determination of imidazoles with variant anti-infective activity in their dosage forms and human plasma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794769/
https://www.ncbi.nlm.nih.gov/pubmed/33396585
http://dx.doi.org/10.3390/molecules26010129
work_keys_str_mv AT aliodayt hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma
AT hassanwafaas hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma
AT khayyatahdabn hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma
AT almalkiahmadj hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma
AT sebaiymahmoudm hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma